Abstract
Abstract
Introduction
The role of PEX26 in colorectal cancer (CRC) development remains unknown. We aimed to study PEX26 expression, regulation, and function in CRC cells.
Methods
By using the databases analysis, real-time quantitative PCR, and immunohistochemistry staining we detected that the expression of PEX26 in CRC and normal tissue. The effect of PEX26 on CRC cells and regulatory mechanism are conducting by functional experiments in vitro.
Results
PEX26 are significantly down-regulated in CRC tissue, and its low expression correlates with the poor overall survival of CRC patients. We further demonstrated that PEX26 over-expression inhibit the ability of CRC cell migration, invasion, and epithelial mesenchymal transition (EMT), while PEX26 knock-down promotes the malignant phenotypes of migration, invasion, and EMT via activating the Wnt pathway.
Conclusions
Overall, our results showed that the loss of PEX26 contributes to the malignant phenotype of CRC. PEX26 may serve as a novel metastasis repressor for CRC.
Publisher
Research Square Platform LLC
Reference41 articles.
1. Computed-Tomography-Determined Sarcopenia is a Useful Imaging Biomarker for Predicting Postoperative Outcomes in Elderly Colorectal Cancer Patients;Xie H;Cancer Res treatment: official J Korean Cancer Association,2020
2. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries;Bray F;Cancer J Clin,2018
3. Tanaka AJ, Okumoto K, Tamura S, Abe Y, Hirsch Y, Deng L, Ekstein J, Chung WK, Fujiki Y. (2019) A newly identified mutation in the PEX26 gene is associated with a milder form of Zellweger spectrum disorder. Cold Spring Harbor molecular case studies 5.
4. Epigenetic Alterations in Colorectal Cancer: Emerging Biomarkers;Okugawa Y;Gastroenterology,2015
5. Alteration of the tumor suppressor SARDH in sporadic colorectal cancer: A functional and transcriptome profiling-based study;He H;Mol Carcinog,2019